In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.

Department of Microbiology, University Hospital of Larissa, Larissa, Greece.
International Journal of Antimicrobial Agents (Impact Factor: 4.26). 09/2008; 32(6):525-8. DOI: 10.1016/j.ijantimicag.2008.05.020
Source: PubMed

ABSTRACT A total of 10420 Gram-positive cocci (including staphylococci, enterococci and various groups of streptococci) collected from clinically significant specimens in ten Greek hospitals during 2006--2007 were tested for their susceptibility to daptomycin. The minimum inhibitory concentration (MIC) was determined by the broth microdilution method. Daptomycin demonstrated very high activity against Enterococcus faecalis (MIC at which 50% of the isolates were inhibited (MIC50) = 1mg/L and MIC at which 90% of the isolates were inhibited (MIC90) = 1.36 mg/L), Enterococcus faecium (MIC50 = 1.36 mg/L and MIC90 = 1.90 mg/L), Streptococcus pyogenes (MIC50 = 0.12 mg/L and MIC90 = 0.50mg/L), Streptococcus agalactiae (MIC50 = 0.09 mg/L and MIC90 = 0.12 mg/L), Streptococcus pneumoniae (MIC50 = 0.24 mg/L and MIC90 = 0.5 mg/L) and viridans group streptococci (MIC50 = 0.50 mg/L and MIC90 = 0.89 mg/L). Resistance to linezolid and vancomycin for enterococci and to penicillin for streptococci appears to be independent of reduced susceptibility to daptomycin. On the other hand, daptomycin was also active against meticillin-resistant Staphylococcus aureus (MIC50 = 0.44 mg/L and MIC90 = 0.78 mg/L) and meticillin-resistant coagulase-negative staphylococci (MIC50 = 0.24 mg/L and MIC90 = 0.44 mg/L); however, 0.9% of the staphylococci tested had an MIC > 1mg/L, which is the Clinical and Laboratory Standards Institute breakpoint proposed for susceptibility. For all tested organism groups, resistance to daptomycin was not associated with glycopeptide resistance.

  • Source
    Journal of Antimicrobial Chemotherapy 12/2010; 66(5):1195-6; author reply 1196-7. · 5.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 14 linezolid-resistant enterococci (6 Enterococcus faecium and 8 Enterococcus faecalis) collected during 2009 from patients hospitalized in intensive care units of different Greek hospitals were investigated. The mechanism of resistance to linezolid was determined by sequencing analysis of the domain V of 23S rDNA, while the clonal relatedness was defined by pulsed-field gel electrophoresis and multilocus sequence typing. All linezolid-resistant enterococci carried the G2576T mutation. E. faecium belonged to the international epidemic clones ST16, ST17, ST203 and ST65, while all E. faecalis strains belonged to the ST28 clone. The spread of common linezolid-resistant enterococcal clones in intensive care units located in different areas of Greece emphasizes the importance of application of infection control measures to prevent the spread of such strains.
    Chemotherapy 01/2011; 57(3):181-5. · 1.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.
    Journal of Antimicrobial Chemotherapy 04/2010; 65(6):1126-36. · 5.34 Impact Factor

Full-text (2 Sources)

Available from
Jun 2, 2014